Avapritinib
Mast Cell Leukemia
Blueprint Medicines CorporationSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Mast Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Stanford University | Phase 2 | BB |
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
FILGRASTIM Stanford University | Phase 2 | B |
Solu-Cortef Stanford University | Phase 2 | B |
Brentuximab Vedotin Jason Robert Gotlib | Phase 2 | B |
View all 24 →
Same molecule, other indications
Avapritinib is also rated in:
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →